Summary: Orally administered drugs suŠer from attack by metabolic enzymes not only in the liver, but also in the gastrointestine during the absorption process across the intestinal tissue. Although kinetic study on hepatic metabolism has been done well, the intestinal metabolism has not been well focused on compared with hepatic metabolism. In order to emphasize the role of intestinal metabolism in drug absorption and bioavailability, I have reviewed the experimental methods for intestinal absorption and metabolism, and the data analysis. Since Klippert et al. reported the prediction of intestinalˆrst-pass eŠect of phenacetin in the rat from enzyme kinetic data in 1982, several reports have showed a good prediction, but others have not. Although intestinal absorption is an integrated process of transport (transporters) and metabolism (metabolic enzymes), most of the researchers missed the pathway of intestinal drug absorption and applied the kinetic model eŠective on only systemic metabolism to presystemic intestinal metabolism for their analysis of intestinal metabolism of orally administered drugs. A kinetic model, which incorporated factors of membrane transport, metabolic activity and protein binding, was structured to compare the equations in the reported models. In conclusion, we need more studies including kinetic modeling and experiments to understand the impact of intestinal metabolism on drug absorption. That knowledge must lead to the construction of ADME in silico (e-ADME).
Introduction
Orally administered drugs have to pass through the intestinal tissue into the intestinal vascular space to exhibit their pharmacological eŠects. The bioavailability of orally administered drugs (F) is determined by the fraction entering the tissue (Fa), which is the fraction neither lost in the feces, nor decomposed in the lumen, the fraction escaping destruction within the walls of the gastrointestinal tract (Fg), and the fraction escaping liver extraction (Fh) (Eq. 1-1, Fig. 1 ).
1)

F＝Fa×Fg×Fh
Eq. 1-1.
Thus, intestinal absorption of a drug is a key process determining bioavailability. Orally administered drugs suŠer from attack by metabolic enzymes not only in the liver, but also in the gastrointestine during the absorption process across the intestinal tissue. Therefore, intestinal absorption is an integrated process of transport (transporters) and metabolism (metabolic enzymes). The relationship between the membrane transport and the metabolism is classiˆed into sequential and parallel processes (Scheme 1).
2) Sequential processes of transport and then metabolism or metabolism and then transport are true for prodrugs. In theˆrst process, the prodrug (or preprodrug) is transported and metabolized, and the active drug formed from the prodrug (or the prodrug from the pre-prodrug) appears in the vascular space. In the second process, the prodrug (or pre-prodrug) is metabolized to form the active drug (prodrug), and this is transported to the vascular side. For example, the disaccharide conjugate of p-nitrophenol was metabolized to the monosaccharide conjugate of p-nitrophenol, and this was transported by the Na + W glucose cotransporter, SGLT1. 3) In the sequential process, a vectorial coopera- LPH, lactase W phloridzin hydrolase; SGLT1, Na + W glucose cotransporter. Fig. 3 . Inverse correlation between absorption and glucuronidation metabolism in the intestinal absorption of 1-naphthol in the rat. 5) Open symbols, in the absence of phloretin (inhibitor of glucuronidation); closed symbols, in the presence of phloretin. 1-Naphthol concentrations: 0.25 mM (squares), 0.5 mM (triangles), 1 mM (circles). The curve was obtained byˆtting the data to the equation based on the metabolic inhibition model. 28) 497 Kinetic Impact of Presystemic Intestinal Metabolism tion of the metabolic enzyme lactase W phloridzin hydrolase (LPH), and the transporter, SGLT1 (Fig. 2) 4) was observed kinetically. 3) On the other hand, the process of transport and metabolism in parallel is true for active drugs. Orally administered drugs have to be transported competitively with metabolism when they are absorbed. The intestinal availability of an orally administered drug is the re‰ec-tion of the competitive parallel process. For example, intestinal glucuronidation decreased drug absorption, and the kinetic correlation between them could be shown by an in vitro experiments (Fig. 3) .
5) However, the intestinal metabolism has not been well focused on compared with hepatic metabolism, although intestinal drug metabolism by oxidation, glucuronidation, sulfation and decarboxylation has been shown. 6) In this review, in order to emphasize the role of intestinal metabolism, I have reviewed the experimental methods for intestinal absorption and metabolism, and the data analysis, emphasizing that intestinal metabolism is the key factor aŠecting drug absorption and bioavailability.
Presystemic and Systemic Intestinal Metabolism
The contribution of intestinal drug metabolism to elimination is classiˆed into 2 types, systemic and presystemic metabolism (Fig. 4) . Based on the physiological model and clearance concept, systemic availability (F), which is expressed as the sequential process of presystemic metabolism in the intestine and liver, is given by Eq. 1-2.
where Qhv and Qpv are the blood ‰ow rates of the hepatic vein and portal vein, respectively; Clhi and Clgi are the intrinsic clearances of the liver and gastrointestine, respectively. Systemic organ clearance (CL) is given by Eq. 1-3. where Q and Cli are the organ blood ‰ow and intrinsic clearance of organ, respectively. Eq. 1-2 clearly shows that presystemic clearance in the intestine is given by the same equation as the systemic organ clearance.
However, this appears strange to me, since there is a diŠerence in the direction of the drug transport through the intestinal tissue between presystemic and systemic metabolism. Furthermore, the presystemic intestinal metabolism directly aŠects the intestinal availability or rst-pass eŠect of an orally administered drug. Therefore, it is time to reconsider the kinetic model for predicting in vivo intestinal metabolism and absorption.
In Vivo and In Vitro Experiments and Data Analysis
Phenacetin: Theˆrst study on the in vivo-in vitro relationship of the intestinal metabolism of an orally administered drug was reported by Klippert et al.
9)
Klippert et al. studied the intestinal O-deethylation metabolism of phenacetin in vivo and in vitro.
In vivo
The intestinal extraction ratio (Eg) was calculated by Eg＝1" AUCpo AUCpv Eq. 1-4.
where AUCpo and AUCpv represented the areas under the blood concentration vs. time curves (AUC) after duodenal (oral) or intraportal administration of the drug, respectively. The Eg was estimated to be 0.53.
In vitro
Intestinal phenacetin-O-deethylation activity in vitro was obtained using an intestinal microsomal fraction of control and 3-MC pretreated rats. Km were 56.7 and 37.6 mM for the control and 3-MC treatment, respectively. Vmax were 0.254 and 2.704 nmol W min W g intestine for the control and 3-MC treatment, respectively. They calculated the intrinsic clearance (Clint) to be 0.143 and 2.30 mL W min W kg body weight for the control and 3-MC treatment, respectively, by assuming 32g small intestine W kg rat. The Eg in vitro was calculated from these values and Eq. 1-5.
Eg＝
Clint fu Q+Clint fu Eq. 1-5.
where Q represented the mucosal blood ‰ow rate. fu was the blood unbound fraction of drug, but fu was 1 in this report. Vmax and Km represented the maximum rate of metabolism and the Michaelis constant, respectively. The Eg was predicted to be 0.31 to 0.53 under the condition of a mucosal blood ‰ow rate of 2.5 to 5.0 mL W min W kg body weight in 3-MC pretreated rats.
Correlation between the in vivo and in vitro data
The Eg predicted from the in vitro data was 0.31 to 0.53, and was comparable to the Eg in vivo, 0.53. This indicates that this approach is highly useful for predict-ing the Eg, and is theˆrst successful example. However, it should be noted that the predictability of Eg is fully in‰uenced by Q.
Fenoterol:
In vivo
Koster et al. calculated the intestinal extraction (Eg) of fenoterol in vivo by Eq. 1-4.
10) The Eg was estimated 0.93.
In vitro
They also obtained 0.55 mL W min W kg rat of intrinsic clearance (Clint) using isolated rat intestinal epithelial cells and Eq. 1-6.
11) Vmax and Km were 228 pmol W min W mg protein and 0.62 mM, respectively. The value was corrected for recovery and viability using 1500 mg intestinal cell proteinW kg rat. From Clint and the equation, the intestinal extraction (Eg) of fenoterol was calculated to be 0.10.
where 5 mL W min W kg rat of Qmuc was used. The value was used in a previous successful study on phenacetin.
5)
However, there was a large diŠerence in the values between the in vivo and vitro studies. They therefore reported that the model cannot be universally used.
Morphine, Naloxone and Buprenorphine: Mistry and Houston studied the glucuronidation of morphine, naloxone and buprenorphine in vivo and in vitro.
12)
They compared the intrinsic clearances (Clint) using the following equations.
In vivo
Clint in vivo was calculated by Clint＝ QEg fu(1"Eg)
Eq. 1-8.
where fu was the unbound fraction in the blood; Q was the mucosal blood ‰ow and assumed to be 4 mL W min W kg body weight. Eg was calculated according to Eq. 1-4. Eq. 1-8 is derived from Eq. 1-5. The intrinsic clearances of morphine, naloxone and buprenorphine were 3, 9 and 30 mL W min W kg rat, respectively. The extraction ratios of morphine, naloxone and buprenorphine were 0.33, 0.57 and 0.48, respectively. Brewster et al. reported 0.8 to be the extraction ratio for buprenorphine using the same equation.
13)
In vitro Rat intestinal microsomes were used to estimate the metabolic activity (Clint calculated by Eq. 1-6), as an in vitro experimental tool. The Clint of morphine, naloxone and buprenorphine were 0.25, 0.5 and 2.3 mL W min W kg body weight, respectively. They reported that the in vivo parameters were 10-to 30-fold higher than the in vitro parameters.
When the extraction ratios of the in vitro study are calculated here using Eq. 1-5, the in vitro intrinsic clearances and blood unbound fractions, the extraction ratios of 0.0379, 0.0676 and 0.0645 are obtained for morphine, naloxone and buprenorphine, respectively. These clearly indicate the large diŠerence in parameters between the in vivo and in vitro studies, and that the predicted extraction ratio using Eq. 1-5 with the in vitro data was underestimated. They concluded that although the in vivo parameters gave measures 10-to 3-fold higher than the in vitro parameters, the rank order was identical for in vivo and in vitro.
Salicylamide: In vivo
Iwamoto et al. estimated the fraction of salicylamide dose subject to gastrointestinal extraction (Eg). 14) Eg＝1" AUCo AUCp Eq. 1-9
where AUCo and AUCp were the AUCs after oral or intraportal administration, respectively, to rats. However, it remains questionable why the drug solution was vascularly perfused in the study of Xu et al. The experiment is eŠective in the estimation of systemic intestinal metabolism, but not of the presystemic intestinal metabolism. Moreover, the equation for the calculation of the in vivo Eg in the report has to be reconrmed.
1-Naphthol: In vivo
Mistry and Houston reported the intestinal extraction ratio in vivo (Eg).
17) It was estimated to be 0.457 by Eq. 1-4.
In vitro
Koster et al. calculated the intrinsic clearance in vitro (Clint) from the enzyme kinetic parameters, which were obtained using microsomes. 
where the absorption clearance (CLabs) was calculated from the appearance rate of 1-naphthol in the vascular perfusate divided by the 1-naphthol concentration in the in‰owing perfusate, and the clearance of 1-naphthol as 1-naphthol glucuronide (Cl NG ) was obtained by dividing the total rate of 1-naphthol glucuronide appearance in the vascular and luminal perfusate by the 1-naphthol concentration in the in‰owing perfusate. The Epre is comparable to that of the in vivo data (0.457), although it was luminal ‰ow rate-dependent and ranged from 0.38 to 0.58. The point to emphasize is that the Epre, which was calculated by the equation without reference to the blood ‰ow rate, was well correlated to the in vivo data.
Hexamethylmelamine: In vivo
The extraction ratio of the gut (Eg) for hexamethylmelamine in rats was calculated by the following equations. 19) Fi
where Fi.d. and Fp.v. were the bioavailability of hexamethylmelamine after intraduodenal or portal vein administration, respectively; AUCi.d., AUCi.v and AUCp.v. were the area under the blood concentration curve of hexamethylmelamine after intraduodenal, intraarterial, and portal vein administration, respectively; Eh and Eg were the extraction ratios of the liver and intestine, respectively. The Eg was estimated to be 0.71.
In vitro
Borm et al. obtained the intestinal extraction ratio (Eg) in vitro using two kinds of experiments. 20) One used microsomes and isolated cells from the rat intestine, and the other used rat everted perfused gut segments. The Michaelis-Menten parameters, Km and Vmax, of the intestinal N-demethylase using microsomes and isolated cells were 55 mM and 5.6 nmolW min W g intestine, and 65 mM and 7.0 nmolW min W g intestine, respectively.
The Eg calculated with the data using microsomes and isolated cells were 0.57 and 0.58, respectively. A mucosal blood ‰ow (Q) of 2.5 mL W min W kg and 32 g small intestine per kg rat was assumed. For the intestinal perfusion experiments, the Eg was calculated by Eq. 1-17.
The total clearance (Cltotal) was assayed by the disappearance of the substrate from the mucosal compartment. where Ktra was the (net) transport rate of the unchanged parent compound from the mucosal to the serosal side; Kmet was the rate by which the intestinal segment metabolized the substrate, and was the summation of the formation rates of all the metabolites on both the serosal and mucosal sides. The Eg was calculated to be 0.75 to 0.90, and this is comparable to the in vivo data (0.71). Borm et al. reported the success for calculation of an``alternative'' extraction ratio, which was derived from the intestinal perfused segments and replacement of the mucosal blood ‰ow with the transport clearance.
CYP3A substrates: Thummel et al. 21) reported an interesting challenge for the prediction of human intestinal metabolic activity. They predicted the intestinal rst-pass extraction ratio (Ei,pred) for CYP3A substrates using literature values for liver microsomal Km and Vmax and by scaling up Vmax from 106 pmol CYP3A W mg liver microsomal protein 22) to a total of 71 nmol CYP3A in the small intestine. The Eg in vitro 
CLabs＝
CLm-i fmuc×CLi-s CLi-m×(1+CLs-i fser W Q)+CLi-s+CLmet,int×(1+CLs-i fser W Q) Eq. ; Clin,u and fu were the intrinsic clearances of the unbound drug in the plasma and the unbound fraction, respectively. However, because of the uncertainties about the impact of plasma protein binding on the intestinalˆrst-pass, they chose to ignore it in their prediction. Oralˆrst-pass (liver and gut) in vivo (E) was calculated by E＝1"F Eq. 1-23
where F was the reported values of bioavailability. 24) They reported that Ei,pred of midazolam and nifedipine, which were 38-54z and 36-52z, respectively, presented the strongest case forˆrst-pass gut metabolism based on 70z (midazolam) and 50z (nifedipine) of E. Wacher et al. could explain the eŠects of CYP3A and P-glycoprotein on cyclosporine absorption using the following equation for intestinal extraction (Eg). 25) Eg＝ kmg kabs+kmg Eq. 1-24
where kmg and kabs were the rate constant for intestinal metabolic elimination and the rate constant for drug appearance in the portal blood, respectively (Fig. 5) .
Here, the deˆnition of the rate constants should be noted. A theoretical approach to understanding the eŠects of intestinal CYP3A4 and P-glycoprotein on drug absorption has also been reported.
26)
Proposal of another kinetic model for intestinal absorption: As shown above, there are various methods for the prediction of the intestinal extraction ratio in vivo from the in vitro data. Therefore, I constructed a kinetic model of the intestinal absorption process consisting of transport, metabolism and blood flow (the TMF model 27) ).
Absorption clearance, CLabs
Eq. 2-1 for the absorption clearance was derived on the basis of the TMF model of intestinal absorption (Fig. 6, Appendix I) .
where CLabs represented the clearance for absorption of drug from the mucosal side to the vascular side, and is deˆned by
Cmuc was the mucosal concentration of the drug. CLmi, CLi-m, CLi-s, CLs-i, CLmet,int and Q were transport clearance from the mucosal side into the intestinal cell, transport clearance from the intestinal cell to the mucosal side, transport clearance from the intestinal cell to the serosal side, transport clearance from the serosal side into the intestinal cell, the intrinsic clearance of metabolism and the mucosal blood ‰ow, respectively. The fmuc and fser represent the unbound fraction of the drug in the mucosal side and blood, respectively. When there are multiple (n) transports or metabolism in each process, such as CLm-i and CLmet,int, the equation may be expressed by When the unstirred water layer cannot be neglected, the intestinal absorption clearance (CLabs,uwl) may be expressed by
where CLuwl is the permeation clearance of the unstirred water layer. In this report, however, it was assumed that the unstirred water layer is not signiˆcant. For the absorption clearance (CLabs,0) in the case of CLmet,int＝0, Eq. 2-1 was expressed by Therefore, the intestinal availability (Fi) may be expressed by Eq. 2-5 indicates that the intestinal availability is dependent not only on the metabolic activity or blood ‰ow rate, but also on the membrane transport. This is clearly diŠerent from the equation based on the Well Stirred model (for example, Eq. 1-5). As described above, transport and metabolism in the absorption process are competitive. Therefore, Eq. 2-5 should be more appropriate for the estimation of presystemic intestinal metabolism (Ei) than Eq. 1-5.
Simulation of absorption and availability
The absorption clearance and availability were simulated according to Eqs. 2-1 and 2-5 ( Figs. 7a and b) . The conditions were CLm-i fmuc＝CLi-m＝0.1×CLs, CLs-i fser＝CLi-s＝CLs and Q was 250 mL W min W body (approximate value of 248 mL W min W body). 23) Figure 7a shows that CLabs increases with CLs, and decreases with CLmet,int. The eŠect of CLmet,int on the availability (Fi) is remarkable when the CLs is lower, indicating the importance of the ratio of CLmet,int to CLs for intestinal availability (Fig. 7b) . Under limited conditions and relevance to the reported models a) When fmuc≒1 and fser≒1, Eqs. 2-1 and 2-3 are simpliˆed to Fig. 7 . EŠects of transport and metabolism on intestinal absorption (a) and availability (b). Absorption clearance (CLabs) and availability (Fi) were simulated according to Eqs. 2-1 and 2-3. The assumed conditions were: CLm-i fmuc＝CLi-m＝0.1×CLs, CLs-i fser＝CLi-s＝CLs and Q was 250 mL W min W body (approximate value of 248 mL W min W body 23) ).
b) In the case of CLs-i fser9Q, Eqs. 2-1 and 2-3 are simpliˆed to
Eq. 2-9
These equations were previously reported by us. 28) c) In the case of CLs-i fser9Q, CLm-i＝CLi-m＝ CLm, CLs-i＝CLi-s＝CLs, and CLm9CLs, Eqs. Further studies required: There are still several factors that remain to be clariˆed in order to understand intestinal metabolism and absorption in vivo. Lin et al. 29) pointed out that the presystemic intestinal extraction ratio is overestimated when the fraction of a given drug absorbed is assumed to be 100z. Also, an underestimation of hepatic ratio will result in an almost proportional overestimation of intestinal extraction. More accurate evaluation of in vivo intestinal metabolism should be required.
The eŠect of protein binding on the extraction ratio is also a critical factor in drug metabolism. Fisher et al. reported the eŠects of extracellular protein binding on theˆrst-pass extraction ratio (ER) of midazolam (MDZ) using cytochrome P-450 (CYP) 3A4-expressing Caco-2 monolayers.
30) The ER was calculated by ER＝ 1?-OH MDZ 1?-OH MDZ+MDZbasolateral where 1?-OH MDZ and MDZbasolateral were the sum of the MDZ metabolite formed and the amount of MDZ in the basolateral compartment, respectively. Basolateral human serum albumin (4z) decreased the MDZˆrst-pass ER from 13.1z (control) to 5.2z, and increased the absorption of MDZ.
Various eŠects of albumin on the kinetic parameters have also been reported using hepatic microsomes. Obach pointed out the importance of nonspeciˆc binding in vitro, 31) and Ludden et al. 32) reported that the addition of albumin to incubation media for microsomes or slices might yield Km estimates that are more representative of the in vivo values. On the other hand, Tang et al. 33) reported that albumin facilitated the hydroxylation of phenytoin and tolbutamide via a decrease in Km. Moreover, even CYP kinetic data has been reported using microsomes, which were not consistent with the Michaelis-Menten model. 34) In conclusion, we should realize that the pathway of orally administered drugs through the intestine is diŠerent from that of the liver, and more studies of experimental methods and kinetic models are required to clarify the impact of intestinal metabolism and transport. These studies are very important for the next issue which is to develop ADME in silico (e-ADME). Absorption rate＝Q×Cser Eq. A-5
Appendix I
CLm-i×Cmuc fmuc"CLi-m×Ciceˆce"CLmet,int×Ciceˆce"CLi-s×Ciceˆce+CLs-i×Cser fser＝0 Eq. A-8
CLi-s×Ciceˆce"CLs-i×Cser fser"Q×Cser＝0 E q . A -9
Therefore, CLabs is derived as follows. Eqs. A-6 and A-7 are expressed as Eqs. A-8 and A-9, respectively.
CLabs＝ Absorption rate Cmuc
